US Market News
15時間前
Halozyme Appoints David Ramsay as President Drug DeliveryJune 30, 2026 4:02 PM
PR Newswire (US) SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026.In this newly created role, Mr. Ramsay will have an enterprise-wide, cross-technology mandate, and will be responsible for driving the growth of Halozyme's drug delivery technologies by establishing clear strategic priorities and assuring best in class business development and alliance management. David will report to Helen Torley, President and Chief Executive Officer."I am delighted to have a business leader of David's experience assume this new position at a time of unprecedented opportunity and growth for Halozyme. In his recent role as Interim Chief Financial Officer, he demonstrated his deep experience and an expansive skillset including strategic assessment, industry and partner knowledge, and, of course, deep financial expertise," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "I look forward to having David assume this newly established leadership role and contribute to the acceleration of value creation for our shareholders."Mr. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale-up.David served as Interim Chief Financial Officer of Halozyme from March 23 to June 8, 2026, until the appointment of Darren Snellgrove as Chief Financial Officer, and was responsible for leading all financial operations for the Company.He previously served as Halozyme's Chief Financial Officer from 2003 to 2009, Vice President of Corporate Development from 2009-2013 and again as Chief Financial Officer from 2013 to 2015, during which time the company evolved from a private enterprise to a billion-dollar public biopharmaceutical company. During his prior tenure as CFO, Mr. Ramsay guided the company through significant growth and played a key role in establishing Halozyme's foundational financial and technology commercialization infrastructure. Previously, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. until its sale to Allergan plc in October 2018."I am thrilled to assume this new role at Halozyme at such an important time in the Company's evolution," said Mr. Ramsay. "Halozyme's broad technology portfolio has tremendous yet untapped potential to dramatically improve the delivery of biologics for millions more patients, collaborating with industry-leading biopharmaceutical partners and resulting in new durable and growing royalty streams. I look forward to working with Helen and the entire team to drive sustainable growth and value creation for shareholders."Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley, and an M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.About HalozymeHalozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., Skye Bioscience and GSK.Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at-home and healthcare-provider settings. The addition of Surf Bio's polymer-based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx,Vertex Pharmaceuticals, and Oruka Therapeutics.Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.For more information, visit www.halozyme.com and connect with us on LinkedIn.Forward-Looking StatementsThis press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, future performance and growth of Halozyme's business. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including but not limited to unexpected levels of revenues and expenses, Halozyme's future growth (including the number of future patients using Halozyme's drug delivery technology) and shareholder value. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.Contacts: Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui @jcamp-8407
sydney.charlton@teneo.com View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-appoints-david-ramsay-as-president-drug-delivery-302815025.htmlSOURCE Halozyme Therapeutics, Inc. Original: Halozyme Appoints David Ramsay as President Drug Delivery
maumar
20時間前
According to JPM, the Myositis indication could add up to $7bn in potential Vyvgart sales. Essentially, Vyvgart could become the next Darzalex for Halo. I believe ARGX's and HALO's recent strength is due to this:
"Upside from Commercial Potential remains very significant, even if only IMNM is statistically significant: Based on the CIDP dosing used in the trial and associated pricing and only treating 50% of the 20,000 IMNM patients, we estimate a $5bn opportunity for Vyvgart in IMNM alone, where we see an increased chance of success given the sizing of the IMNM part of the ALKIVIA trial. The DM opportunity would generate further upside with only 10% share of the 40,000 patients leading to a further $2bn in sales, we estimate. With every $1bn in sales worth around JPMe €40/$50 per share, we see potential for a successful result in IMNM alone de-risking a $5bn potential for Vyvgart in Myositis to drive the shares to €950/$1,100."
Argenx
Takeaways from the Myositis R&D Spotlight session
By Richard Vosser AC, Sophia Graeff Buhl Nielsen AC, Zain Ebrahim, Khushi Bihani, Dhitee Goel
Click here for the full document and disclaimers
ARGX.BR, ARGX BB
Overweight
Price (23 Jun 26):€813.00
ARGX, ARGX US
Overweight
Price (23 Jun 26):$853.40
Yesterday we attended the R&D spotlight session for Autoimmune Myositis in Boston. Here, Argenx disclosed further information regarding the subgroup patient population in the Phase II trial, where IMNM patients constituted c.60% of patients and demonstrated a statistically significant result in this subgroup alone, and DM patients (c.30% of patients) also showed a clear signal of efficacy, albeit with this subgroup not sufficiently powered to show a stat sig benefit in Phase II. Given that Phase II enrollment recruited in similar proportions to Phase III, Argenx will now analyse the primary end point for Phase III in IMNM and DM separately and file on this basis, and given a limited number of patients in PM they now no longer see a registrational path for PM. With yesterday’s session providing more insight around the potential efficacy and powering of the IMNM portion of the ALKIVIA trial, we this as further de-risking the opportunity for Vyvgart in IMNM, which we expect could be c.$5bn in itself assuming a 50% penetration of the 20k patient population. Furthermore, we continue to see a path forward for Vyvgart in DM, where despite greater heterogeneity in the patients and a small number of patients enrolled increasing the risk around whether this part of the phase III trial is sufficiently powered for a stat sig result, KOLs see the need for multiple different treatment options and the potential for combination use in this broader patient population (40k). Overall, while we expect there might be some concerns over the potential for success in DM, we see yesterday’s session as further de-risking the potential for Vyvgart in IMNM, which we estimate alone has the potential to add €150 per share to current levels, assuming success in ALKIVIA, with further upside should the DM portion of the trial also deliver a stat sig result.
Phase III analysis plan: Argenx highlighted that they are splitting up the Phase III (ALKIVIA) trial effectively into two separate trials, which they will separately seek regulatory filing for:
IMNM, which represents 60% of the 176 patients in Phase III – or c. 106 patients, which will separately be analysed for success. We assume that this will be separately analysed for statistical significance at p
Minninv
5日前
chat GPT
LifeMD and Halozyme announce exclusive Telehealth co-marketing agreement for XYOSTED self-pay program launching july 2026 what is this agreement about how much revenue will halozyme gain per year does LifeMD pay Halozymme anything up front
This announcement is strategically positive for Halozyme, but investors should be careful not to overestimate its near-term financial impact.
What is the agreement?
Halozyme's subsidiary, Antares Pharma, entered into an exclusive telehealth co-marketing agreement with LifeMD to create a direct-to-patient self-pay program for XYOSTED, which begins in July 2026 and initially covers 37 states.
Here's how it works:
Men with symptoms of low testosterone visit the LifeMD platform.
They have a virtual consultation with a licensed clinician.
If appropriate, laboratory testing confirms hypogonadism.
If prescribed, XYOSTED is shipped directly to the patient's home through LifeMD's pharmacy.
The program costs approximately $249 per month, including the medication and medical care, without requiring insurance.
Why did Halozyme do this?
Halozyme wants to make it much easier for men to obtain XYOSTED.
Instead of:
finding a physician,
obtaining prior authorization,
visiting a specialty pharmacy,
patients can complete almost everything online.
This should:
increase awareness of testosterone deficiency,
increase prescriptions,
improve patient adherence,
allow Halozyme to reach men who might otherwise never start therapy.
Does LifeMD pay Halozyme anything up front?
There is no announcement of any upfront payment.
The press release and SEC filing state that:
the companies entered into a Master Services Agreement, a Statement of Work, and Specialty Pharmacy Agreements;
they will jointly invest in consumer education and marketing.
There is no disclosed signing fee, licensing payment, milestone payment, or upfront cash payment from LifeMD to Halozyme.
How does Halozyme make money?
Halozyme earns money primarily by:
selling XYOSTED to the dispensing pharmacy,
increasing prescription volume as more patients enroll.
LifeMD earns money by:
providing telehealth visits,
pharmacy services,
ongoing patient management.
Both companies share the cost of promoting the program.
How much additional revenue could Halozyme receive?
No guidance has been provided, so any estimate is speculative.
Using the announced price of about $249 per month, here's what the program could look like if patients stay on therapy for a year:
Average active patients Program sales (approx.)
2,500 ~$7.5 million/year
5,000 ~$15 million/year
10,000 ~$30 million/year
20,000 ~$60 million/year
Not all of that would become Halozyme revenue because the $249 includes:
physician care,
laboratory testing,
pharmacy services,
the medication.
The exact revenue split has not been disclosed.
Could it become significant?
Potentially, yes.
Before Halozyme acquired Antares, XYOSTED had annual sales of only around $70–80 million. If telehealth substantially expands adoption, annual sales could eventually exceed $100 million or more, although there is no guarantee. Given Halozyme's 2026 revenue guidance of roughly $1.7–1.8 billion, even an additional $20–50 million per year would not materially change the company's overall financial results, but it could improve the growth profile of its proprietary products.
Bottom line
The agreement appears to be a commercial distribution and marketing partnership, not a licensing deal.
No upfront payment from LifeMD has been disclosed.
Halozyme and LifeMD will co-market the program.
Halozyme benefits if prescription volumes increase.
The agreement could add millions of dollars in annual XYOSTED sales, but based on the available information it is unlikely to add hundreds of millions of dollars per year unless the program grows far beyond its initial launch.
As a Halozyme shareholder, I'd view this as a smart strategic move that strengthens the company's proprietary-product business, but it is not likely to be a major earnings driver in the first year.
Minninv
5日前
ChatGPT
Claim offer
is this a true statement What’s the point? Halozyme is bound to collapse in the end.Halozyme will lose to Merck, and its PH20 (hyaluronidase) patent will be invalidated; meanwhile, Alteogen will soar and eventually grow into a company several times the size of Halozyme. Can a company grow that much overnight? While capital is currently concentrated in the AI ??semiconductor sector—leaving other sectors starved of investment—Alteogen is ultimately destined to become a company many times larger than Halozyme.
The short answer is no. That statement is not a factual statement—it is a highly speculative opinion that presents predictions as if they are certain.
Here's a breakdown:
"Halozyme is bound to collapse in the end."
There is no evidence that Halozyme is "bound" to collapse.
Halozyme has a profitable business with multiple commercial partners.
It generates substantial royalty and licensing revenue from its ENHANZE technology.
The company has cash flow, approved products using its technology, and multiple partnerships.
A company can certainly face challenges, but saying it is "bound to collapse" is speculation, not fact.
"Halozyme will lose to Merck."
No one knows the outcome until the legal process is complete.
Patent litigation is unpredictable. Possible outcomes include:
Halozyme wins.
Merck wins.
A settlement.
Some patents upheld while others are narrowed or invalidated.
Anyone claiming they know the outcome is guessing.
"Its PH20 patent will be invalidated."
Again, this is speculation.
Patent challenges happen frequently in the pharmaceutical industry. Some patents survive completely, some are partially invalidated, and some are overturned. Until the relevant proceedings are complete, no one can state with certainty that Halozyme's patents will be invalidated.
"Alteogen will soar and become several times larger than Halozyme."
That is also a prediction—not a fact.
Alteogen has promising technology and has attracted licensing interest, but:
It still must execute commercially.
Drug development and licensing involve significant risk.
Future market capitalization depends on many unpredictable factors.
Many biotechnology companies that once looked extremely promising later disappointed investors.
"Can a company grow that much overnight?"
No.
Even when biotech stocks rise dramatically after major news, companies do not typically become several times larger overnight in a sustainable way.
For example:
A major licensing deal may cause a stock to jump 30–100%.
Exceptional events can produce larger temporary gains.
Becoming 5–10 times larger usually takes years of successful execution, not days.
Why do people post statements like this?
Comments like this are common on stock message boards and social media. They often reflect:
Personal opinion
Emotion
Fear
Optimism
Attempts to influence sentiment
They should not be treated as investment facts.
Looking at Halozyme objectively
Halozyme still has several strengths:
Multiple commercial partners using its ENHANZE platform.
Recurring royalty revenue.
Strong profitability compared with many biotechnology companies.
Ongoing efforts to expand indications and partnerships.
Its biggest uncertainty is the intellectual property landscape, including litigation involving Merck and increasing competition from newer hyaluronidase technologies. Those are real risks, but they do not automatically imply the company will fail.
Overall: I would view the statement you quoted as bearish opinion rather than factual analysis. It makes absolute claims ("bound to collapse," "will lose," "will be invalidated," "destined") that simply cannot be known today. Investors should instead weigh the evidence on both the opportunities and the risks rather than relying on certainty from either overly bullish or overly bearish commentary.
biotechinvestor1
2週前
What Merck Is Arguing
Merck’s counsel (Leif Peterson, Sidley Austin) filed on June 12, 2026 seeking clarification on two procedural issues:
Issue 1: Two Separate Director Review Requests
• Paper 140 (May 26, 2026): “Patent Owner’s Request for Director Review of Order Denying Patent Owner’s Motion to Terminate” — challenges the interlocutory termination denial order • Paper 142 (June 11, 2026): “Patent Owner’s Request for Director Review of the Final Written Decision” — challenges the final written decision itself
Merck argues Paper 140 was procedurally improper because 37 C.F.R. § 42.75(a) says you can only seek Director Review of a “final decision” concluding the proceeding — not an interlocutory order (the termination denial).
Issue 2: Improper Incorporation by ReferenceMerck argues that Paper 142 incorporates Paper 140 “by reference,” which violates 37 C.F.R. § 42.6(a)(3) (no incorporation by reference between documents). By combining the arguments, Halozyme allegedly exceeded the 15-page limit.
The Director’s Response (June 16, 2026 — TODAY)
What the Director Authorized:“Petitioner is authorized only to respond to arguments presented in Patent Owner’s Request for Director Review of the Final Written Decision, filed on June 11, 2026 (Paper 142).”
Analysis: What This Means
1. The Director Has NOT Ruled on Merck’s Procedural Objections
The Director’s email is procedurally silent on Merck’s two challenges:
• No ruling on whether Paper 140 was procedurally improper • No ruling on the incorporation-by-reference/page-limit issue • No ruling on whether Merck gets to file a separate response to Paper 140
What this likely means: The Director is NOT addressing these procedural niceties and is instead going to rule on the merits of the RPI issue on Paper 142. The Director is essentially saying: “I’m going to consider Paper 142 as filed. You can respond to it. I’ll decide the case based on what’s before me.”
2. Merck’s Procedural Arguments Are Being Sidelined
Merck’s objections were legally technical but organizationally smart — they’re trying to:
• Delay the Director’s decision by forcing separate briefing on the “procedurally improper” Paper 140 • Complicate the Director’s analysis by fragmenting Halozyme’s arguments • Limit Halozyme’s written pages by eliminating the incorporation by reference
The Director has essentially rejected this strategy. By authorizing Merck to respond only to Paper 142 (not separately to Paper 140), and authorizing no further briefing, the Director is signaling:
“I’m going to make a decision on the RPI issue as presented. No more delays. No more procedural games.”
3. The 5-Business-Day Timeline Is Aggressive
Merck has until June 23, 2026 to file its 15-page authorized response. This is a tight timeline — and the Director’s use of it signals the final decision could come very soon after (days or weeks).
Why this matters: The Director is moving fast. A fast Director Review decision typically reflects either:
• A clear legal issue the Director wants to resolve quickly, OR • A Director who views the case as relatively straightforward and doesn’t need extensive briefing
Given the RPI issue, this is probably the former: the Director knows the May 15 precedent on PGR2025-00087 creates logical inconsistency with the ‘600 FWD, and he’s moving to resolve it.
Revised Probability Assessment
This procedural order strengthens Halozyme’s position in three specific ways:
1. The Director is NOT entertaining Merck’s delay tactics.If the Director were skeptical of Halozyme’s RPI arguments, he would likely grant Merck’s request for separate briefing on Paper 140 — giving him more time to think, more material to work with. Instead, he’s closing off additional briefing and moving to decision.
2. Incorporating Paper 140’s arguments into Paper 142 (implicitly approved) means the full RPI control/funding/benefit argument stays in front of the Director.Merck tried to fragment it procedurally. The Director rejected that attempt.
3. The fast timeline suggests the Director views this as a straightforward legal issue.The May 15 precedent on PGR2025-00087 makes the RPI defect analysis parallel. The Director can resolve it quickly by applying consistent logic.
Revised Director Review Probability
|Outcome |Prior |Post-June 16 Order||---------------------------------------------------------------------|------|------------------||Director denies review, FWD stands |15-22%|**10-15%** ||Director grants review, affirms denial |8-12% |**5-8%** ||Director grants review, **reverses — vacates FWD, terminates -00003**|65-75%|**77-85%** |
Why the upward shift:
• Director rejected Merck’s delay/obstruction tactics • Fast timeline + no additional briefing = Director views this as straightforward • The implicit approval of Halozyme’s combined arguments means the full control/funding/benefit case stays intact
What Merck Should Do Now
Merck’s counsel now faces a strategic choice:
Option A (Recommended): File a strong 15-page response on the merits of the RPI issue, explaining why the May 15 PGR2025-00087 precedent doesn’t apply, or distinguishing it. This is their last chance.
Option B (High Risk): Continue procedural objections in the response (arguing the incorporation-by-reference issue, etc.). This will likely annoy the Director and won’t change the outcome.
Merck should go with Option A — a substantive RPI defense that directly addresses why MCI is NOT an RPI despite the May 15 precedent.
Bottom Line
The Director has signaled his intent to move forward decisively. He’s rejected Merck’s procedural delays. He’s authorizing Merck’s response but nothing more. This is the body language of a Director who:
1. Understands the RPI issue deeply (May 15 precedent made that clear) 2. Views Halozyme’s May 26/June 11 petitions as legally sufficient 3. Intends to rule — probably in Halozyme’s favor — within weeks of Merck’s June 23 response
Revised settlement/licensing probability: 77-85% — up from 75-82% — because the Director Review appears to be moving toward reversal at an accelerating pace.
The next milestone is Merck’s June 23 response. That will be the final argument before Director Squires decides whether to vacate the ’600 FWD and terminate PGR2025-00003 on RPI grounds.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
メールアドレスで登録
